Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab. Issue 4 (5th August 2016)

• Record Type: Journal Article
• Authors: Mumtaz, Saqib; Goh, Jason; Hirschfield, Gideon M; Ferguson, James; Cooper, Sheldon C
• Is Part Of: Frontline gastroenterology. Volume 7:Issue 4(2016)
• Page Start: 271
• Page End: 274
• Publication Date: 2016-08-05
• Subjects: PRIMARY SCLEROSING CHOLANGITIS -- ULCERATIVE COLITIS -- LIVER TRANSPLANTATION; Gastroenterology -- Periodicals; 616.33005
• DOI: 10.1136/flgastro-2016-100711
• Languages: English
• ISSNs: 2041-4137

Abstract

Abstract : Primary sclerosing cholangitis (PSC) is associated with inflammatory bowel disease (IBD) in approximately 70% of patients, with ulcerative colitis (UC) being the most common subtype of IBD identified. There is a paucity of data on the optimum management strategy for IBD flares in the post-liver transplant patient, particularly when refractory to conventional treatments. Vedolizumab is a novel gut-specific monoclonal antibody, which has recently been approved for use by National Institute for Health and Care Excellence for moderate-to-severe UC. We present an exemplar case of successful use of vedolizumab in the management of corticosteroid refractory PSC-IBD after liver transplantation.